Corebridge Financial Inc. Boosts Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Corebridge Financial Inc. grew its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 21.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,499 shares of the company’s stock after buying an additional 5,765 shares during the quarter. Corebridge Financial Inc.’s holdings in EyePoint Pharmaceuticals were worth $242,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter valued at about $59,000. AlphaQuest LLC lifted its stake in shares of EyePoint Pharmaceuticals by 13,246.6% in the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock worth $73,000 after acquiring an additional 9,670 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter worth approximately $76,000. China Universal Asset Management Co. Ltd. increased its stake in shares of EyePoint Pharmaceuticals by 40.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock worth $108,000 after buying an additional 4,179 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of EyePoint Pharmaceuticals by 22.4% in the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock worth $113,000 after purchasing an additional 2,782 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Up 12.1 %

Shares of EyePoint Pharmaceuticals stock opened at $5.38 on Friday. The business has a fifty day simple moving average of $6.04 and a 200-day simple moving average of $7.91. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $23.65. The firm has a market cap of $369.76 million, a price-to-earnings ratio of -2.69 and a beta of 1.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. Analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EYPT has been the topic of several research analyst reports. Citigroup initiated coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $33.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.